BROMOCRIPTINE CONCENTRATION IN SALIVA AND PLASMA AFTER LONG-TERM TREATMENT OF PATIENTS WITH PARKINSONS-DISEASE
BROMOCRIPTINE CONCENTRATION IN SALIVA AND PLASMA AFTER LONG-TERM TREATMENT OF PATIENTS WITH PARKINSONS-DISEASE
复制标题
DOI：
10.1007/bf00561586
复制
发表时间：
1980-01-01
影响因子：
2.9
通讯作者：
PAKKENBERG, H
中科院分区：
文献类型：
--
作者：
FRIIS, ML;JOHNSEN, T;PAKKENBERG, H
Salivary and plasma concentrations of bromocriptine (BCT [2-bromo-.alpha.-ergocryptine, Parlodel]), a dopamine agonist, were measured by gas chromatography in 4 patients with Parkinson''s disease. All patients were on mono-therapy with BCT for years, and during the 3 wk prior to the investigation they received constant but individually different dosage regimens. Paired samples of pure, parotid, serous saliva and of blood were collected hourly during one 8 h dose interval. The concentrations of BCT in saliva were very low and there was a 10-fold range in the areas under the salivary and plasma concentration/time curves. In clinical practice measurement of BCT in saliva is not suitable for exact estimation of the plasma concentration of BCT. Using the measured salivary pH and the plasma BCT concentration, calculations based on the Henderson-Hasselbalch equation showed that the assumption of .apprx. 99% plasma protein binding of BCT best fitted the observed concentrations of BCT in saliva.
